Straits Times Index
3,304.04 -18.04 (-0.54%) Nikkei
39,134.79 +96.63 (+0.25%) Hang Seng
18,169.07 -197.88 (-1.08%) FTSE 100
8,239.11 +10.63 (+0.13%) Bitcoin USD
67,788.85 -1,658.37 (-2.39%) CMC Crypto 200
1,403.04 -38.60 (-2.68%)
Xilio Therapeutics, Inc. (XLO)
After hours:
| Previous close | 1.0500 |
| Open | 1.0600 |
| Bid | 1.0400 x 100 |
| Ask | 1.1000 x 100 |
| Day's range | 1.0400 - 1.1250 |
| 52-week range | 0.4900 - 3.0000 |
| Volume | |
| Avg. volume | 1,330,758 |
| Market cap | 39.127M |
| Beta (5Y monthly) | -0.04 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.5700 |
| Earnings date | 01 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.50 |
GlobeNewswireXilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results
Expect to initiate Phase 2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with microsatellite stable colorectal cancer (MSS CRC) in the third quarter of 2024 Plan to report clinical data for XTX101 and XTX301, a tumor-activated IL-12, in the fourth quarter of 2024 Advancing research-stage pipeline of tumor-activated bispecifics and immune cell engagers Anticipate cash runway into the second quarter of 2025 WALTHAM, Mass., May 14, 2024 (
ZacksXilio's (XLO) Shares Surge 79.8% in a Month: Here's Why
Xilio (XLO) rallies 79.8% in a month on an exclusive global licensing agreement with Gilead Sciences to develop XTX301 for advanced solid tumors.
- GlobeNewswire
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
On track with plans to initiate Phase 2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with microsatellite stable colorectal cancer (MSS CRC) in the third quarter of 2024 Granted Gilead exclusive license to develop and commercialize XTX301, a tumor-activated IL-12 Anticipates cash runway into the second quarter of 2025 WALTHAM, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnolo
